Sendas Distributor S.A 6-K, filed Feb 19, 2021
Sendas Distributor S.A. (ASAIY)
About this 6-K
Sendas Distributor S.A filed this 6-K on February 19, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or
15d-16 of the Securities Exchange Act of 1934
For the month of February 2021
Commission File Number: 001-39928
Sendas Distribuidora S.A.
(Exact Name as Specified in its Charter)
Sendas Distributor S.A.
(Translation of registrant’s name into English)
Avenida Ayrton Senna, No. 6,000, Lote 2, Pal 48959, Anexo A
Jacarepaguá
22775-005 Rio de Janeiro, RJ, Brazil
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)
Form 20-F: ☒ Form 40-F: ☐
(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)):
Yes: ☐ No: ☒
(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)):
Yes: ☐ No: ☒
EXHIBIT INDEX
Exhibit Number |
Description of Document |
| 99.1 | Press Release - CBD and Sendas Announce Spin-Off Details. |
| 99.2 | Joint Material Fact dated February 19, 2021 (English translation). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 19, 2021
| Sendas Distribuidora S.A. | ||
| By: | /s/ Daniela Sabbag Papa | |
| Name: | Daniela Sabbag Papa | |
| Title: | Chief Financial Officer and Investor Relations Officer | |
2
Exhibit 99.1
![]() |
![]() |
CBD and Sendas Announce Spin-Off Details
São Paulo, February 19, 2021 – Companhia Brasileira de Distribuição (B3: PCAR3; NYSE: CBD) (“CBD”) and Sendas Distribuidora S.A. (“Sendas”) announce that on February 19, 2021, the Securities and Exchange Commission (“SEC”) declared effective the Registration Statement on Form 20-F (the “Registration Statement”) relating to the spin-off of Sendas to the shareholders of CBD (the “Spin-Off”) pursuant to the terms described in the Registration Statement.
The Spin-Off was previously approved by the shareholders of CBD, and CBD as the sole shareholder of Sendas, at extraordinary shareholders’ meetings held on December 31, 2020.
In connection with the Spin-Off, each holder of CBD common shares will receive one Sendas common share for each CBD common share held at close of trading on February 26, 2021 (the “Brazilian Record Date”), on the B3 S.A. – Brasil, Bolsa, Balcão (“B3”). Beginning on March 1, 2021, Sendas common shares are expected to commence trading on a standalone basis on the B3 under the ticker symbol “ASAI3”. On that date, CBD common shares will trade on the B3 “ex-distribution,” without the right to receive Sendas shares in the distribution. The distribution of Sendas common shares in Brazil is expected to settle on March 3, 2021 (the “Brazilian Distribution Date”).
Each holder of American Depositary Shares (“ADSs”) of CBD (each representing one CBD common share) will be entitled to receive one newly-issued Sendas ADS (each representing one Sendas common share) for each CBD ADS held at close of trading on March 2, 2021 (the “ADS Record Date”), on the New York Stock Exchange (“NYSE”). The distribution of Sendas ADSs is expected to occur on March 5, 2021 (the “ADS Distribution Date”).
Sendas ADSs are expected to begin trading on a “when-issued” basis on the NYSE from market open on March 1, 2021 and continue up to and including March 5, 2021, under the ticker symbol “ASAI WI”. Trades in the “when-issued” market are expected to settle on March 10, 2021. Sendas ADSs are expected to commence “regular-way” trading on a standalone basis on the NYSE at market open on March 8, 2021, under the ticker symbol “ASAI”. Trades in the “regular-way” market are expected to settle within the standard settlement cycle, which is the second business day after the trade.
Beginning on March 1, 2021 (the day prior to the ADS Record Date), and continuing through the close of trading on the NYSE on March 5, 2021 (the ADS Distribution Date), the markets for CBD ADSs will be the following:
| ● | CBD ADS “regular-way” market (NYSE: CBD): CBD ADSs that trade in the “regular-way” market will trade with “due bills,” which are entitlements to Sendas ADSs to be distributed in the Spin-Off. Any holders of CBD ADSs who sell CBD ADSs the “regular-way” between March 1, 2021 and March 5, 2021 will also be selling their right to receive Sendas ADSs in connection with the Spin-Off. Trades in the “regular-way” market are expected to settle within the standard settlement cycle, which is the second business day after the trade. |
| ● | CBD ADSs “ex-distribution” market (NYSE: CBD WI): CBD ADSs that trade in the “ex-distribution” market will trade without an entitlement to Sendas ADSs to be distributed in the Spin-Off. Any holders of CBD ADSs as of the ADS Record Date who sell CBD ADSs in the “ex-distribution” market between March 1, 2021 and March 5, 2021 will still receive Sendas ADSs in connection with the Spin-Off. Trades in the “ex-distribution” market are expected to settle on March 10, 2021. |
JPMorgan Chase Bank, N.A., as CBD ADS Depositary, will suspend the issuance and cancellation of CBD ADSs from the close of business on February 26, 2021 until the close of business on March 10, 2021. This means that during this time, holders of CBD ADSs will not be able to surrender their CBD ADSs and receive underlying CBD common shares, and holders of CBD common shares will not be able to deposit their CBD common shares and receive CBD ADSs. However, the closing of the issuance and cancellation books does not impact trading, and holders of CBD ADSs may continue to trade their CBD ADSs during this period.
Holders of CBD common shares or CBD ADSs will not be required to take any action, pay any cash, deliver any other consideration, or surrender any existing CBD common shares or CBD ADSs in order to receive Sendas common shares or Sendas ADSs in the Spin-Off, except that if you hold CBD ADSs through DTC, you will be required to pay an issuance fee of US$0.03 per Sendas ADS issued to JPMorgan Chase Bank, N.A., as Sendas ADS Depositary, in order to receive Sendas ADSs.
Holders of CBD common shares CBD ADSs are encouraged to consult with their financial and tax advisors regarding the specific implications of the Spin-Off, including the specific implications of buying or selling CBD ADSs on or before the ADS distribution date and the U.S. federal, state and local or foreign tax consequences, as applicable, of the Spin-Off.
The Registration Statement includes information regarding the Spin-Off, the separation of CBD and Sendas, as well as other important information. The Registration Statement is available on the SEC’s website at www.sec.gov and on Sendas’s website at www.assai.com.br/informacoes-financeiras
Special Notice Regarding Forward-Looking Statements:
This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that reflect the current expectations of the management of CBD and Sendas. These statements include, but are not limited to, statements about the completion of the Spin-Off, timing of “when-issued” and “regular-way” trading and trading on the NYSE and the B3 and other non-historical matters. These statements are based on management’s current expectations or beliefs, and are subject to uncertainty and changes in circumstances. These forward looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause the actual results to differ materially from those indicated in our forward looking statements. You are cautioned not to put undue reliance on such forward-looking statements. Neither CBD nor Sendas undertakes any obligation, and expressly disclaims any obligation, to update or revise any forward-looking statements.
Exhibit 99.2
![]() |
|
|
COMPANHIA BRASILEIRA
DE Publicly-held Company CNPJ/ME No. 47.508.411/0001-56 NIRE 35.300.089.901 |
SENDAS DISTRIBUIDORA S.A. Publicly-held Company CNPJ/ME No. 06.057.223/0001-71 NIRE 33.300.272.909 |
JOINT MATERIAL FACT
Companhia Brasileira de Distribuição (“GPA”) and Sendas Distribuidora S.A. (“Sendas”), pursuant to Article 157 of the Brazilian Law No. 6,404/1976 and CVM Instruction 358/2002, hereby informs its shareholders and the market, in continuity with the disclosures previously made by each of the companies, that: (i) on February 10, 2021, it was approved the request for listing and admission to the trading of Sendas shares in the Novo Mercado segment of the B3 S.A. – Brasil, Bolsa, Balcão (“B3”); and (ii) on February 12, 2021, it was approved the request for listing of Sendas American Depositary Securities (“ADSs”) representing its common shares on the New York Stock Exchange (“NYSE”), (jointly, the “Listings”).
The Listings take place in the context of the corporate reorganization of GPA and Sendas, approved at Extraordinary Shareholders’ Meetings of both companies, held on December 31, 2020, which approved (i) Sendas’ partial spin-off, with the purpose of segregating the participation of Sendas in Almacenes Éxito SA and the transfer of certain operating assets, with the incorporation of the spun-off portion into GPA; and (ii) GPA’s partial spin-off, aiming to segregate the total shareholding interest that GPA holds in Sendas, and the delivery of the common shares issued by Sendas that are currently owned by GPA directly to GPA’s shareholders, at a ratio of one common share of Sendas for each common share issued by GPA.
GPA’s shareholders will receive, after the close of trading on February 26, 2021 (“Cut-off Date”), shares issued by Sendas, in proportion to their respective holdings in the capital stock of GPA. The common shares issued by GPA will be traded “with the right to receive shares issued by Sendas” under the ticker symbol “PCAR3” until the Cut-off Date, whilst as of March 1, 2021, GPA’s common shares will be traded “ex-distribution”, without the right to receive Sendas shares in the distribution and Sendas shares will be traded in the Novo Mercado segment under the ticker symbol “ASAI3”.
Sendas ADSs will be traded on the NYSE as of March 1, 2021 and continue up to and including March 5, 2021 on a “when-issued” basis under the ticker symbol “ASAI WI”. Sendas ADSs are expected to commence “regular-way” trading on March 8, 2021, under the ticker symbol “ASAI”. More information on the process and listing dates for Sendas ADSs is available in the specific notice published today on the SEC’s website and on GPA’s and Sendas’ websites at www.sec.gov, www.gpari.com.br and www.assai.com.br/informacoes-financeiras, respectively.
São Paulo, February 19, 2021.
|
Christophe José Hidalgo Interim
Chief Executive Officer, Vice |
Daniela Sabbag Papa Chief Financial and Investor Relations |
Special Notice Regarding Forward-Looking Statements:
This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that reflect the current expectations of the management of GPA and Sendas. These statements include, but are not limited to, statements about the completion of the Spin-Off, timing of “when-issued” and “regular-way” trading and trading on the NYSE and the B3 and other non-historical matters. These statements are based on management’s current expectations or beliefs, and are subject to uncertainty and changes in circumstances. These forward looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause the actual results to differ materially from those indicated in our forward looking statements. You are cautioned not to put undue reliance on such forward-looking statements. Neither GPA nor Sendas undertakes any obligation, and expressly disclaims any obligation, to update or revise any forward-looking statements.


